NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - May 19, 2014) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at the following scientific and industry conferences this month.
MIXiii Biomed Israel Innovation Conference
Mr. Chaim Lebovits, BrainStorm's President, will present at the MIXiii Biomed Israel Innovation Conference organized by the Israel Advanced Technologies Industries, May 20-22 in Tel Aviv. Mr. Lebovits will participate in a panel discussion entitled "Deal Making with Academy" on May 20th at 17:15.
Joint Congress of European Neurology
Professor Dimitrios Karussis, Principal Investigator of BrainStorm's clinical trials at Jerusalem's Hadassah Medical Center, will present at the Joint Congress of European Neurology, May 31-June 3 in Istanbul, Turkey. Prof. Karussis' oral presentation, entitled "Analysis of patients with amyotrophic lateral sclerosis (ALS) treated with autologous differentiated mesenchymal stem cells: a phase I/II and IIa clinical trial" will be in the Motor Neurone Diseases Session on June 1st, 16:45 - 18:15.
Dr. Yael Gothelf, BrainStorm's VP Scientific and Regulatory Affairs, will present at the Israstem 2014 Conference, June 10-11 in Ramat Gan, Israel. Dr. Gothelf's oral presentation, entitled "Clinical Trials with Autologous Bone Marrow-Derived Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients with Amyotrophic Lateral Sclerosis (ALS)," will be on June 11th at 11:00 a.m.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.